Carregant...
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
BACKGROUND: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as th...
Guardat en:
| Publicat a: | Neurol Sci |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8223191/ https://ncbi.nlm.nih.gov/pubmed/34165650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10072-021-05409-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|